KSCM
BIOTW

Kamunting Street Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Kamunting Street Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-158,962
Closed -$38K – 49
2022
Q1 		$38K Buy
+158,962
New +$50.7K 0.05% 31
2021
Q3 		– Sell
-158,962
Closed -$137K – 95
2021
Q2 		$137K Buy
+158,962
New +$110K 0.06% 79

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Kamunting Street Capital Management's BIOTW Position: Q2 2022 in Review

Kamunting Street Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q2 2022, closing a stake of 158,962 shares — an estimated $38K sold.

Kamunting Street Capital Management first reported a position in BIOTW in Q2 2021 and held it in 2 quarters. The position peaked at $137K in Q2 2021. 48 funds tracked by Wall St. Rank hold BIOTW as of Q2 2022.

  • Kamunting Street Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q2 2022 after selling out during the quarter.
  • Kamunting Street Capital Management sold 158,962 Biotech Acquisition Company Warrant shares in Q2 2022, an estimated $38K.
  • Kamunting Street Capital Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 2 quarters.
  • Kamunting Street Capital Management's Biotech Acquisition Company Warrant position peaked at $137K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q2 2022.

Based on Kamunting Street Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.